Search

everythinglearnresearchcommunity

for

Search:↓

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

ZDHHC13 is important for normal liver function and metabolism, affecting mitochondrial activity.

CYLD deficiency in skin tumors disrupts hair follicle cell processes and protein secretion.

A specific gene variant is linked to heart disease, increased heart muscle, curly hair, and thick skin on palms and soles.

A new method accurately detects illegal JAK inhibitors in hair loss cosmetics.

Ruxolitinib can help regrow hair in severe alopecia areata.

Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

The new method found new shared genetic areas linked to both Type 2 Diabetes and Prostate Cancer.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Inhibiting TYK2 can restore hair growth in alopecia areata.

Mutations in the ACTB gene cause Becker’s nevi and may lead to muscle issues in Becker’s nevus syndrome.

Majocchi's granuloma can occur in kidney transplant patients on tacrolimus and can be treated with antifungal medication.

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

GATA6 is important for maintaining and differentiating cells in a key area of human skin.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

PTEN was identified as a specific marker for the skin disease cutaneous lupus erythematosus, and it helps increase the expression of harmful type I interferons.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Baricitinib can cause excessive hair growth.

Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.